Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Bellevue Biotech (CH)

ISIN-No.: CH0113817123

YTD: 12.77%

Active share: 44.97

Number of positions: 50

Biotech sector with sustainable, strong sales and earnings growth thanks to high innovation level   

 Expiring patents of pharma companies lead to high M&A activity (patent cliff)

Valuations very attractive on historical average over the last 10 years

Indexed performance (as at: 13.11.2026)

NAV: CHF 4'767.53 (15.11.2026)


01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display
DT-CHF
NBI

Rolling performance (13.11.2026)

DT-CHFNBI
15.11.2025 - 15.11.202614.54%38.10%
15.11.2024 - 15.11.202516.87%12.30%
15.11.2023 - 15.11.202415.57%16.23%
15.11.2022 - 15.11.2023-19.31%-16.84%

Annualized performance (13.11.2026)

DT-CHFNBI
1 year14.54%38.10%
3 years15.66%21.70%
5 years2.77%6.32%
10 years5.25%7.11%
Since Inception p.a.10.19%12.70%

Cumulative performance (13.11.2026)

DT-CHFNBI
1M4.68%4.32%
YTD12.77%33.68%
1 year14.54%38.10%
3 years54.71%80.27%
5 years14.62%35.87%
10 years66.79%98.66%
Since Inception376.75%584.79%

Annual performance

DT-CHFNBI
202517.01%15.73%
20247.48%6.69%
2023-8.57%-5.57%
2022-9.83%-9.88%

Investment Focus

The Bellevue Biotech fund focuses on the most promising companies in the biotechnology sector. The fund actively invests in 30 to 50 stocks that have met all of the stringent selection criteria applied by us. These are biotech companies that have specialized in areas such as immunology, virology, neurology, oncology, cardiology, endocrinology, etc. Geographically, the fund’s investments are concentrated in North America, Europe and Asia. The fund takes ESG factors into consideration while implementing the aforementioned investment objectives.Show moreShow less

Investment suitability & Risk

SRI

Low risk

High risk

The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.

General Information

Investment ManagerBellevue Asset Management AG
CustodianZürcher Kantonalbank
Fund AdministratorSwisscanto Fondsleitung AG
AuditorErnst & Young AG
Launch date15.10.2010
Year end closing30. Sep
NAV CalculationDaily "Forward Pricing"
Cut of time15:00 CET
Management Fee1.20%
Subscription Fee (max.)2.50%
Performance Fee10.00% (with High Water Mark)
ISIN numberCH0113817123
Valor number11381712
BloombergADGLBII SW
WKNA1H8PS

Legal Information

Legal formInvestment funds under Swiss law
SFDR categoryArticle 8
Redemption periodDaily

Key data (31.10.2026, base currency CHF)

Beta0.87
Volatility20.09
Tracking error7.49
Active share44.97
Correlation0.94
Sharpe ratio0.88
Information ratio-0.80
Jensen's alpha-4.32
No. of positions50

Top 10 positions

Amgen
Gilead Sciences
Vertex Pharmaceuticals
Alkermes
Royalty Pharma
Eli Lilly
Viatris
Revolution Medicines
Illumina
Bridgebio Pharma
9.3%
9.2%
9.0%
4.2%
4.1%
3.8%
3.6%
3.5%
3.3%
2.8%

Market capitalization

0 - 1 bn
1 - 2 bn
2 - 5 bn
5 - 15 bn
15 - 20 bn
> 20 bn
Others
1.7%
4.4%
3.4%
22.7%
7.6%
59.5%
0.8%

Geographic breakdown

United States
Other
Netherlands
China
Switzerland
Cash
81.9%
5.4%
3.8%
2.5%
2.5%
3.9%

Breakdown by sector

Oncology
Specialty Pharma
Infectious Diseases
Pulmonary Diseases
Orphan Diseases
Other
Neurolog. Disorders
Autoimmune disease
Metabolic Diseases
Cardiovascular
Life Science Supply
Cash
24.2%
12.4%
10.7%
9.0%
9.0%
7.9%
6.8%
5.2%
3.8%
3.7%
3.3%
3.9%

Benefits

  • New innovative drugs are powering sustainable momentum in the biotech sector.
  • Attractively valued large cap biotechs.
  • Expiring pharmaceutical patents trigger a rise in M&A activity.
  • Focus on US biotech companies with strong growth potential.
  • Bellevue Healthcare team – top-performing pioneer in the management of healthcare portfolios.

Risks

  • The fund actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
  • Biotech equities can be subject to sudden substantial price movements owing to market, sector or company factors.
  • The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
  • Investing in emerging markets entails the additional risk of political and social instability.
  • The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund’s liquidity.

Global equities continued to be mixed in October, with the MSCI World Index down -2.1% in CHF on a net return basis. The S&P 500 returned -2.2% in CHF while the NASDAQ Composite returned -6.5%, weighed by a selloff in the tech and AI space.

Healthcare strongly outperformed, with the MSCI World Health Care Index up 8.4% in CHF on a net return basis during the month of October.

October was a challenging month for markets, with the broad market finishing slightly in the red. The primary headwind was a broad selloff in the tech and AI space, which weighed on sentiment across risk assets. This was further compounded by a risk-off tone ahead of the early November midterm elections, persistently elevated yields, and continued market expectations of at least one additional interest rate hike by the Federal Reserve before year-end.

In the healthcare space, the month's main events centered on the first wave of Q3 earnings from many of the sector's larger constituents. Results were broadly constructive and helped insulate healthcare from the wider market weakness.

Large-cap biopharma was the largest contributor to sector performance during the month, underpinned by solid earnings beats and guidance raises. The segment also benefitted from a rotation into defensive names, both from investors moving out of tech and from within the sector itself.

Overall, end-market demand across the sector remains robust, driven by a combination of ongoing therapeutic innovation and structurally increasing healthcare consumption across key demographics.

The biotechnology segment (NBI; +2.9% in USD, +1.6% in CHF) underperformed broader healthcare in October.

The Bellevue Biotech (CH) fund (ADGLBII shares) returned -2.3% in CHF, outperforming its benchmark by 77 bp.

Top absolute performers in the fund included Genmab (+59.9%; Phase III wins for petosemtamab in head and neck cancer, Rina-S in ovarian cancer and Epkinly in DLBCL), Eli Lilly (+22.5%; Q3 beat and third guidance raise of the year to USD 91-92 bn), and Viridian Therapeutics (+19.8%; positive broker checks on the Lumvoa launch).

Top relative positive contributors included Eli Lilly (overweight; +76 bp; Q3 beat and third guidance raise of the year to USD 91-92 bn), Alnylam Pharmaceuticals (not invested; +73 bp; slowing Amvuttra growth, 340B reimbursement risk and UnitedHealth Medicare Advantage restrictions), and Genmab (overweight; +50 bp; Phase 3 wins for petosemtamab in head and neck cancer, Rina-S in ovarian cancer and Epkinly in DLBCL).

Top relative negative contributors included Regeneron (not invested; -115 bp; Q3 beat on Dupixent and Eylea HD, expanded Sanofi alliance), Moderna (not invested; -84 bp; Nasdaq-100 inclusion and cancer vaccine enthusiasm despite mid-month selloff on INTerpath-001 data), and Agomab Therapeutics (overweight; -50 bp; selloff after 48-week STENOVA open-label extension data).

Biotechnology may be entering a more durable phase of growth after years of structural, regulatory, and capital-market headwinds. The sector is transitioning from a speculative, capital-intensive model toward sustainable, cash-generative growth, driven by premium pricing, leaner cost structures, and disciplined capital allocation. Fundamentals are stabilizing, and investor confidence is returning as the industry increasingly achieves sustainable profitability.

Long-term structural drivers remain compelling. Aging populations, expanding healthcare access in emerging markets, and accelerating innovation in AI-enabled drug discovery, precision medicine, and advanced biologics continue to broaden the opportunity set.

The fund maintains a selective, high-conviction strategy oriented toward late-stage, de-risked assets, proven pricing power, and scalable platforms capable of generating sustainable free cash flow.

Loading...

Show moreShow less

  • Portfolio Manager

    Marcel Fritsch

    Marcel Fritsch has been with Bellevue Asset Management since 2008. He is head of healthcare funds & mandates and co-lead portfolio manager of the Bellevue Medtech & Services, Bellevue Digital Health and Bellevue AI Health funds. Prior to that, he worked as a consultant at Deloitte Touche Tohmatsu for over 3 years. His tasks in this function included analysis of business strategies, assessment of organizational structures and the valuation of companies in the run-up to corporate transactions. Marcel Fritsch holds a degree in business administration from the University of St. Gallen (HSG).
  • Senior Equity Analyst

    Guy Bettschart

    Guy Bettschart joined Bellevue Asset Management in 2025 as a Senior Equity Analyst. Previously, he spent two years as a buy-side healthcare analyst at Kieger AG and worked for Julius Baer in Zurich as a member of its equity research Team. Bettschart holds a BA in Banking & Finance from the University of Zurich and an MSc in Finance from the University of Lausanne and is a CFA Charterholder.
  • Equity Analyst

    Markus Schweiger

    Dr. Markus Schweiger joined Bellevue Asset Management in 2025 as an Equity Analyst. Previously, he worked for Oppenheimer & Co. in New York for two years as a biotech analyst. He holds a PhD in cancer biology (Vrije Universiteit Amsterdam / Massachusetts General Hospital), a dual MSc in neuroscience (Berlin/Amsterdam) and a BSc in psychology.
1

These insights might interest you